These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells. Lee MY; Robbins Y; Sievers C; Friedman J; Abdul Sater H; Clavijo PE; Judd N; Tsong E; Silvin C; Soon-Shiong P; Padget MR; Schlom J; Hodge J; Hinrichs C; Allen C J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33741731 [TBL] [Abstract][Full Text] [Related]
4. Overexpression of DAPK1-mediated inhibition of IKKβ/CSN5/PD-L1 axis enhances natural killer cell killing ability and inhibits tumor immune evasion in gastric cancer. Guo Z; Zhou C; Zhou L; Wang Z; Zhu X; Mu X Cell Immunol; 2022 Feb; 372():104469. PubMed ID: 35114597 [TBL] [Abstract][Full Text] [Related]
5. Increased expression of programmed cell death protein 1 on NK cells inhibits NK-cell-mediated anti-tumor function and indicates poor prognosis in digestive cancers. Liu Y; Cheng Y; Xu Y; Wang Z; Du X; Li C; Peng J; Gao L; Liang X; Ma C Oncogene; 2017 Nov; 36(44):6143-6153. PubMed ID: 28692048 [TBL] [Abstract][Full Text] [Related]
6. Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape. Jiang X; Wang J; Deng X; Xiong F; Ge J; Xiang B; Wu X; Ma J; Zhou M; Li X; Li Y; Li G; Xiong W; Guo C; Zeng Z Mol Cancer; 2019 Jan; 18(1):10. PubMed ID: 30646912 [TBL] [Abstract][Full Text] [Related]
7. Immune evasion via PD-1/PD-L1 on NK cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL. Vari F; Arpon D; Keane C; Hertzberg MS; Talaulikar D; Jain S; Cui Q; Han E; Tobin J; Bird R; Cross D; Hernandez A; Gould C; Birch S; Gandhi MK Blood; 2018 Apr; 131(16):1809-1819. PubMed ID: 29449276 [TBL] [Abstract][Full Text] [Related]
11. An inhibitor of programmed death ligand 1 enhances natural killer cell-mediated immunity against malignant melanoma cells. Lee YS; Heo W; Choi HJ; Cho HR; Nam JH; Ki YG; Lee HR; Son WC; Park YS; Kang CD; Bae J PLoS One; 2021; 16(4):e0248870. PubMed ID: 33793576 [TBL] [Abstract][Full Text] [Related]
12. Study and analysis of antitumor resistance mechanism of PD1/PD-L1 immune checkpoint blocker. Wang Z; Wu X Cancer Med; 2020 Nov; 9(21):8086-8121. PubMed ID: 32875727 [TBL] [Abstract][Full Text] [Related]
13. Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. Li CW; Lim SO; Xia W; Lee HH; Chan LC; Kuo CW; Khoo KH; Chang SS; Cha JH; Kim T; Hsu JL; Wu Y; Hsu JM; Yamaguchi H; Ding Q; Wang Y; Yao J; Lee CC; Wu HJ; Sahin AA; Allison JP; Yu D; Hortobagyi GN; Hung MC Nat Commun; 2016 Aug; 7():12632. PubMed ID: 27572267 [TBL] [Abstract][Full Text] [Related]
14. Regulation of PD-L1: a novel role of pro-survival signalling in cancer. Chen J; Jiang CC; Jin L; Zhang XD Ann Oncol; 2016 Mar; 27(3):409-16. PubMed ID: 26681673 [TBL] [Abstract][Full Text] [Related]
15. Activation of NK cells and disruption of PD-L1/PD-1 axis: two different ways for lenalidomide to block myeloma progression. Giuliani M; Janji B; Berchem G Oncotarget; 2017 Apr; 8(14):24031-24044. PubMed ID: 28199990 [TBL] [Abstract][Full Text] [Related]
16. Bone marrow-derived mesenchymal stem cells inhibit CD8 Liu Z; Mi F; Han M; Tian M; Deng L; Meng N; Luo J; Fu R Clin Exp Immunol; 2021 Jul; 205(1):53-62. PubMed ID: 33735518 [TBL] [Abstract][Full Text] [Related]
17. PD-1 Trefny MP; Kaiser M; Stanczak MA; Herzig P; Savic S; Wiese M; Lardinois D; Läubli H; Uhlenbrock F; Zippelius A Cancer Immunol Immunother; 2020 Aug; 69(8):1505-1517. PubMed ID: 32296919 [TBL] [Abstract][Full Text] [Related]
18. PD-1/PD-L1 in Cancer: Pathophysiological, Diagnostic and Therapeutic Aspects. Munari E; Mariotti FR; Quatrini L; Bertoglio P; Tumino N; Vacca P; Eccher A; Ciompi F; Brunelli M; Martignoni G; Bogina G; Moretta L Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34066087 [TBL] [Abstract][Full Text] [Related]
19. Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Chen G; Huang AC; Zhang W; Zhang G; Wu M; Xu W; Yu Z; Yang J; Wang B; Sun H; Xia H; Man Q; Zhong W; Antelo LF; Wu B; Xiong X; Liu X; Guan L; Li T; Liu S; Yang R; Lu Y; Dong L; McGettigan S; Somasundaram R; Radhakrishnan R; Mills G; Lu Y; Kim J; Chen YH; Dong H; Zhao Y; Karakousis GC; Mitchell TC; Schuchter LM; Herlyn M; Wherry EJ; Xu X; Guo W Nature; 2018 Aug; 560(7718):382-386. PubMed ID: 30089911 [TBL] [Abstract][Full Text] [Related]
20. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells. Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]